Gilead Sciences has entered into an option and license deal with Kymera Therapeutics to support the development and sales of ...

Gilead Sciences and Kymera Therapeutics have entered into a partnership worth as much as $750m to develop a molecular glue ...

Gilead Sciences (NASDAQ:GILD) and Kymera Therapeutics (NASDAQ:KYMR) announced an exclusive partnership on Wednesday to ...

Kymera Therapeutics is celebrating the signing of two partnerships, with Gilead Sciences taking an option on one molecular ...

Kymera Therapeutics, Inc.'s stock rose on KT-621 data, but Sanofi's exit casts doubts. A Gilead Sciences, Inc. deal offers ...

Kymera Therapeutics may have signed a $750 million deal with Gilead, but the Watertown biotech also suffered a setback in its ...

Kymera Therapeutics sweetened news of a setback Wednesday, revealing that Sanofi is pulling back from its lead IRAK4 degrader ...

Gilead Sciences, Inc. (NASDAQ: GILD) and Kymera Therapeutics, Inc. (NASDAQ: KYMR), today announced that they have entered ...

Under terms of the deal, Kymera will lead early research on novel oral CDK2 degraders for solid tumors, with Gilead assuming ...

Sanofi to advance Kymera’s next-generation oral IRAK4 degrader development candidate, KT-485, into clinical testing and will not advance KT-474 In preclinical testing, KT-485 demonstrated increased ...

The biotech will work on molecular glue degraders with Gilead in a new deal. Existing partner Sanofi changed its focus to a ...

Kymera on Wednesday said Sanofi won't advance KT-474, which in late 2023 entered Phase 2 studies trials in patients with the inflammatory skin diseases hidradenitis suppurativa and atopic dermatitis.